Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Samuel Large, Robert Hettle, Arun Balakumaran, Elise Wu & Rebekah H. Borse. (2019) Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective. Journal of Medical Economics 22:1, pages 16-25.
Read now
Read now
Li Gao, Xixi Xiang, Cheng Zhang, Lei Gao, Tonghua Yang, Sanbin Wang, Bin Li, Shifeng Lou, Yi Su, Yao Liu & Xi Zhang. (2019) Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study. Hematology 24:1, pages 225-231.
Read now
Read now
Simonetta Viviani & Anna Guidetti. (2018) Efficacy of antibody–drug conjugate brentuximab vedotin in treating Hodgkin’s lymphoma. Expert Opinion on Biological Therapy 18:8, pages 841-849.
Read now
Read now
Theodoros Karantanos, Ioannis Politikos & Vassiliki A Boussiotis. (2017) Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood and Lymphatic Cancer: Targets and Therapy 7, pages 37-52.
Read now
Read now
Massimo Martino, Moreno Festuccia, Roberta Fedele, Giuseppe Console, Michele Cimminiello, Paolo Gavarotti & Benedetto Bruno. (2016) Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. Expert Opinion on Biological Therapy 16:3, pages 347-364.
Read now
Read now
Articles from other publishers (24)
Liana Nikolaenko & Auayporn Nademanee. (2020) Brentuximab vedotin and its use in the treatment of advanced Hodgkin’s lymphoma. Future Oncology 16:29, pages 2273-2282.
Crossref
Crossref
Nancy Bartlett & Grace Triska. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
1911
1925.e3
.
Paul J. Bröckelmann & Lena Specht. 2020. Hodgkin Lymphoma. Hodgkin Lymphoma
145
169
.
Nitika Paudel, Derek Schulze, Ryan D. Gentzler, Andrew M. Evens, Irene Helenowski, Gary Dillehay, Olga Frankfurt, Jayesh Mehta, Eric D. Donnelly, Leo I. Gordon, Jane N. Winter & Bharat B. Mittal. (2019) Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics 104:2, pages 436-446.
Crossref
Crossref
Peter H. Wiernik. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
903
937
.
A. Guidetti, A. Mazzocchi, R. Miceli, E. Paterno’, F. Taverna, F. Spina, F. Crippa, L. Farina, P. Corradini, A.M. Gianni & S. Viviani. (2017) Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research 62, pages 91-97.
Crossref
Crossref
Yakup Bozkaya, Doğan Uncu, Simten Dağdaş, Gökmen Umut Erdem, Mutlu Doğan, Gülsüm Özet & Nurullah Zengin. (2016) Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center. Indian Journal of Hematology and Blood Transfusion 33:3, pages 361-369.
Crossref
Crossref
Lindsay M. Morton, Wael Saber, K. Scott Baker, A. John Barrett, Smita Bhatia, Eric A. Engels, Shahinaz M. Gadalla, David E. Kleiner, Steven Pavletic & Linda J. Burns. (2017) National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation 23:3, pages 367-378.
Crossref
Crossref
Antonino Carbone, Annunziata Gloghini, Luca Castagna, Armando Santoro & Carmelo Carlo-Stella. (2015) Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. The Journal of Pathology 237:1, pages 4-13.
Crossref
Crossref
Carmelo Carlo-Stella & Armando Santoro. (2015) Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. Biomarkers in Medicine 9:8, pages 807-817.
Crossref
Crossref
Miguel-Angel Perales, Izaskun Ceberio, Philippe Armand, Linda J. Burns, Robert Chen, Peter D. Cole, Andrew M. Evens, Ginna G. Laport, Craig H. Moskowitz, Uday Popat, Nishitha M. Reddy, Thomas C. Shea, Julie M. Vose, Jeffrey Schriber, Bipin N. Savani & Paul A. Carpenter. (2015) Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 21:6, pages 971-983.
Crossref
Crossref
Patricia A. FordShakira J. GrantRosemarie MickGina Keck. (2015) Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. Journal of Clinical Oncology 33:15, pages 1674-1679.
Crossref
Crossref
Lena Specht & Dirk Hasenclever. 2015. Hodgkin Lymphoma. Hodgkin Lymphoma
131
155
.
Anna Guidetti, Carmelo Carlo-Stella, Silvia L. Locatelli, Walter Malorni, Roberta Mortarini, Simonetta Viviani, Domenico Russo, Alfonso Marchianò, Roberto Sorasio, Anna Dodero, Lucia Farina, Laura Giordano, Massimo Di Nicola, Andrea Anichini, Paolo Corradini & Alessandro M. Gianni. (2014) Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research 20:22, pages 5641-5651.
Crossref
Crossref
Nancy L. Bartlett & Kelley V. Foyil. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
2018
2032.e4
.
Maureen M. O’Brien, Michael J. Absalon, Thomas G. Gross & Kara M. Kelly. 2014. Hematopoietic Cell Transplantation in Children with Cancer. Hematopoietic Cell Transplantation in Children with Cancer
251
301
.
Kwonoh Park, Dok Hyun Yoon, Shin Kim, Chan-Sik Park, Jooryung Huh, Sang-Wook Lee & Cheolwon Suh. (2013) High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma. International Journal of Hematology 97:2, pages 256-262.
Crossref
Crossref
Peter H. Wiernik, Monica Balzarotti & Armando Santoro. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
985
1013
.
William Townsend & David Linch. (2012) Hodgkin's lymphoma in adults. The Lancet 380:9844, pages 836-847.
Crossref
Crossref
Anna Guidetti, Carmelo Carlo‐Stella, Silvia L. Locatelli, Walter Malorni, Marina Pierdominici, Cristiana Barbati, Roberta Mortarini, Lilli Devizzi, Paola Matteucci, Alfonso Marchianò, Rodolfo Lanocita, Lucia Farina, Anna Dodero, Corrado Tarella, Massimo Di Nicola, Paolo Corradini, Andrea Anichini & Alessandro M. Gianni. (2012)
Phase
II
study of sorafenib in patients with relapsed or refractory lymphoma
. British Journal of Haematology 158:1, pages 108-119.
Crossref
Crossref
Sarah F. Keller, Jennifer L. Kelly, Elizabeth Sensenig, Jennifer Andreozzi, Jamie Oliva, Lynn Rich, Louis Constine, Michael Becker, Gordon Phillips, Jane Liesveld, Richard I. Fisher, Steven H. Bernstein & Jonathan W. Friedberg. (2012) Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin?s Lymphoma (HL) in the ABVD Therapeutic Era. Biology of Blood and Marrow Transplantation 18:4, pages 640-647.
Crossref
Crossref
Ranjana Advani. (2011) Optimal Therapy of Advanced Hodgkin Lymphoma. Hematology 2011:1, pages 310-316.
Crossref
Crossref
SARA AQUINO, MARINO CLAVIO, EDOARDO ROSSI, LUANA VIGNOLO, MAURIZIO MIGLINO, MAURO SPRIANO, LETIZIA CANEPA, GIOACCHINO CATANIA, IVANA PIERRI, MICAELA BERGAMASCHI, ROBERTA GONELLA, CARLO MARANI, OMAR RACCHI, MARINA CAVALIERE, RICCARDO GORETTI, FEDERICO CARBONE, ANDREA BRUZZONE, RODOLFO TASSARA, ANGELO MICHELE CARELLA, RICCARDO GHIO & MARCO GOBBI. (2011) Therapy of Hodgkin’s lymphoma in clinical practice: A retrospective long-term follow-up analysis. Oncology Letters 2:2, pages 289-295.
Crossref
Crossref
Paolo Corradini, Barbara Sarina & Lucia Farina. (2011) Allogeneic transplantation for Hodgkin’s lymphoma. British Journal of Haematology 152:3, pages 261-272.
Crossref
Crossref